Aventis Ends Peptor Collaboration
Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. In 2003, Aventis generated sales of ? 16.79 billion, invested ? 2.86 billion in research and development and employed approximately 69,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France. For more information, please visit: www.aventis.com
Statements in this news release containing projections or estimates of revenues, income, earnings per share, capital expenditures, capital structure, or other financial items; plans and objectives relating to future operations, products, or services; future economic performance; or assumptions underlying or relating to any such statements, are forward-looking statements subject to risks and uncertainties.
Actual results could differ materially depending on factors such as the timing and effects of regulatory actions, the results of clinical trials, the company?s relative success developing and gaining market acceptance for new products, the outcome of significant litigation, and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission and in the current Annual Report -\"Document de R?f?rence\"- on file with the \"Commission des Op?rations de Bourse\" in France.
Pursuant to Article 7 of the COB Regulation no. 2002-04, this press release was transmitted to the Autorit? des march?s financiers before its release.
Aventis Press Release
Adapted by MNT from original media release